ISM2

Across TCGA pan-cancer cohorts, ISM2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ISM2 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ISM2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ISM2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

HNSC, LIHC, and LUAD are the cancer types where ISM2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.182	0.686	.003	15	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
LUAD	OS	Median	III,IV	0.223	0.677	.006	9	view →
SKCM	DFS	Median	III,IV	1.000	0.577	.034	4	view →
BLCA	OS	Median	III,IV	0.183	0.546	.020	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ISM2–HNSC (OS)

Open the HNSC breakdown →